Corriente Advisors

Omnitron Sensors specializes in developing advanced sensor technologies aimed at enhancing the safety and performance of autonomous vehicles, including self-driving cars and drones. The company harnesses innovative silicon photonics processes to create high-performance, cost-effective sensors designed for safety-critical applications. By providing tools that facilitate the full autonomy of these vehicles, Omnitron Sensors plays a crucial role in making driverless technology safer and more reliable for consumers and industries alike.

Omnitron Sensors specializes in developing advanced sensor technologies aimed at enhancing the safety and performance of autonomous vehicles, including self-driving cars and drones. The company harnesses innovative silicon photonics processes to create high-performance, cost-effective sensors designed for safety-critical applications. By providing tools that facilitate the full autonomy of these vehicles, Omnitron Sensors plays a crucial role in making driverless technology safer and more reliable for consumers and industries alike.

Neurologix, Inc. is a clinical-stage biotechnology company based in Fort Lee, New Jersey, focused on the discovery and development of gene transfer therapies for serious brain and central nervous system disorders. Established in 1999, the company aims to provide therapeutic alternatives to conventional surgical and pharmacological treatments. Its primary research centers on gene therapy for Parkinson's disease and epilepsy, both of which significantly impact patients' quality of life. Additionally, Neurologix is involved in the development of gene transfers for various neurodegenerative and metabolic disorders, including Huntington's disease, depression, and genetically-based obesity. The company's innovative approach seeks to address unmet medical needs by leveraging cutting-edge gene therapy technologies.